Introduction {#s0005}
============

Loss of tissue microarchitecture is a prominent feature of cancer driven by alterations in the composition and quality of the extracellular matrix (ECM) [@bb0005]. The major components of the ECM are the collagens of which 28 different molecules have been described [@bb0010]. Some of these collagens are good and some are bad [@bb0015]. In particular type VI collagen (COL6) is interesting in the context of cancer [@bb0020]. The expression of COL6 is altered in several solid tumor types including pancreatic cancer, breast cancer, colon cancer, melanomas, ovarian cancer, lung cancer and salivary cancer where it associate with proliferative signaling, invasion and metastasis, resisting of cell death, induction of angiogenesis, tumor inflammation and response to chemo- and radiotherapy [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065].

COL6 is a beaded filament collagen found in close proximity of the basement membrane that take part in maintaining epithelial- and endothelial-cell polarity [@bb0070], [@bb0075]. Fibroblasts, tumor cells hematopoietic cells and chondrocytes can also bind to COL6 [@bb0080], [@bb0085], [@bb0090]. COL6 remodeling is linked to tumor progression mediated by an accumulation of activated cancer associated fibroblast and increased matrix metalloprotease (MMP) activity [@bb0020], [@bb0095], [@bb0100], [@bb0105].

COL6 is primarily composed of three different alpha chains, COL6a1, COL6a2 and COL6a3 [@bb0110]. The three alpha chains form heterotrimeric tetramers within the cell. These tetramers are subsequently secreted into the extracellular surroundings where they associate into microfibrils. Several sub-domains in the N- and C-terminal of COL6 are involved in the triple helix and microfibril formation. The so-called C1 subdomain assists in the triple helix formation, the N5 subdomain of the a3 chain is suggested to be involved in the assembly of microfibrils and the C5 subdomain of the a3 chain is important for mature microfibril formation and is immediately cleaved off after secretion [@bb0115], [@bb0120], [@bb0125], [@bb0130]. Interestingly, part of the C5 domain of the a3 chain is also known as endothrophin, a molecule with potent pro-tumorigenic signaling capacity [@bb0025], [@bb0045], [@bb0050], [@bb0055].

While the importance of COL6 in cancer is well established less is known regarding the COL6 biomarker potential. Due to the loss of COL6 homeostasis in the tumor, pathologically relevant COL6 fragments may be generated and released into the circulation. These specific COL6 fragment could potentially be used as cancer biomarkers in the clinical setting.

The aim of this study was to evaluate the potential of four biomarkers targeting unique peptide-epitopes on COL6 in serum from patients with various solid tumors in comparison with healthy controls. Moreover, the aim was to analyze the association between turnover of different COL6-chains (COL6a1 and COL6a3) in the same patient. An overview of the four biomarkers and their specific target is given in [Figure 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}.Figure 1Schematic illustration of s type VI collagen (COL6) tetramer consisting of a1, a2, and a3 heterotrimers and with illustrations of the COL6 biomarker targets (C6Ma1, C6Ma3, IC-6 and PRO-C6) measured in serum. Details of the biomarkers can be found in [Table 1](#t0005){ref-type="table"}.Figure 1Table 1Type VI collagen (COL6) serum biomarker overviewTable 1NameDescriptionAmino acid sequenceC6Ma1MMP-generated epitope on a1 chain573'.YRGPEGPQGP'581C6Ma3MMP-generated epitope on a3 chain2279'GPKGGIGNRG.'2288PRO-C6C-terminal of a3 chain (endothrophin)3168'KPGVISVMGT'3177IC-6Internal epitope on a1 chain216'ADWGQSRDAEEAISQ'230

Methods {#s0010}
=======

Study Subjects {#s0015}
--------------

Serum samples from cancer patients (n = 65) were supplied by Asterand (Detroit, MI, USA). Serum samples from the healthy controls (n = 13) were supplied by Valley BioMedical (Winchester, VA, USA). Samples were collected after informed consent and approval by the local Ethics Committee and in compliance with the Helsinki Declaration of 1975. All serum samples from cancer patients were collected prior to resection. According to the suppliers, samples were collected, processed and stored in a similar fashion. All analyses were performed blindly. An overview of the included subjects is shown in [Table 2](#t0010){ref-type="table"}.Table 2Subject characteristics.Table 2GroupNo. of patientsStageGender,Age, years,1234Unk.% femalemedian (range)Breast cancer8-62\--88%57 (51--68)Colon cancer7-34\--86%63 (49--72)Gastric cancer73121-43%65 (58--81)[⁎](#tf0005){ref-type="table-fn"}Malignant melanoma4121\--25%58 (43--64)NSCLC10423-130%58 (47--80)SCLC71231-29%58 (46--82)Ovarian cancer8125\--100%57 (37--74)Pancreas cancer41-1-275%66.5 (56--69)Prostate cancer1019\-\--0%63 (57--72)[⁎](#tf0005){ref-type="table-fn"}Healthy controls13\-\-\-\--23%53 (39--63)[^1]

Measurements of COL-6 Fragments in Serum {#s0020}
----------------------------------------

Four different COL-6 protein fragments (biomarkers) were measured in serum by well-characterized and validated competitive ELISAs, according to manufacturer\'s instructions (Nordic Bioscience, Herlev, Denmark). The specific C6Ma1, C6Ma3 and IC-6 target epitopes were identified by mass spec analysis (Nordic Bioscience, Herlev, Denmark) and PRO-C6 was identified by sequence analysis of the C-terminal of Col6a3 according to Uniprot database [@bb0135]. In brief, the biomarkers ware assayed as follows: a 96-well streptavidin-plates were coated with biotinylated synthetic target-peptide dissolved in assay buffer. The plate then incubated for 30 minutes at 20°C. The plate was washed five times in 20 mM Tris, 50 mM NaCl, pH 7.2 (wash-buffer). Then, 20 μL of peptide calibrator or sample was added to the appropriate wells followed immediately by the addition of either 100 μL of a Horse Radish Peroxidase (HRP)-conjugated target-specific monoclonal antibody or 100 μL of an unconjugated target-specific monoclonal antibody. The plate was incubated for 1 hour at 20°C or overnight at 4°C, depending on the assay and was then washed five times in wash-buffer. For the assays using unconjugated target-specific monoclonal antibodies, 100 μL of HRP-conjugated secondary IgG antibody (Thermo Scientific, Waltham, MA, USA; cat. \#31437) diluted in assay buffer was added and the plate incubated for an additional hour and then washed five times in wash-buffer. Finally, 100 μL Tetramethylbenzidine (Kem-En-Tec Diagnostics, Taastrup, Denmark) was added and the plates incubated for 15 minutes at 20°C in darkness before adding 100 μL stopping solution 1% H~2~SO~4~ to stop the reaction. The optical density (OD) of each well was measured at 450 nm with 650 nm as reference.

Statistical Analysis {#s0025}
--------------------

Biomarker levels measured in serum from controls were compared to individual patient groups by a Kruskal-Wallis test adjusted for multiple comparisons with Dunn\'s test. Tumor stages (1 + 2 vs 3 + 4) and gender (not shown) were compared by the Mann--Whitney test. Diagnostic accuracy (controls vs 'all cancers') was evaluated by calculating the area under the receiver operating characteristics (AUROC) curve for each biomarker. The correlation between the individual biomarkers and biomarkers and age (not shown) were evaluated by Spearman\'s correlation coefficient (r). Statistical analyses were performed using MedCalc Statistical Software v.12 (Ostend, Belgium). Results were considered statistically significant if *P* \< .05.

Results {#s0030}
=======

Specific Fragments of COL6a1 and COL6a3 are Elevated in Serum from Patients with Various Cancer Indications Compared to Healthy Controls {#s0035}
----------------------------------------------------------------------------------------------------------------------------------------

Serum levels of four different COL6 fragments (see [Table 1](#t0005){ref-type="table"}/[Figure 1](#f0005){ref-type="fig"} for details) were measured by ELISA in healthy controls and in patients with various solid tumor types. To exclude that the biomarker levels were driven by age or gender, the four COL6 fragments were correlated with age and evaluated according to gender (data not shown). No association was found between the COL6 fragments and age or gender.

As shown in [Figure 2](#f0010){ref-type="fig"}, overall the two MMP-generated fragments (C6Ma1 and C6Ma3) were significantly elevated in most of the different cancer indications compared to controls. In contrast, the two other COL6 fragments (IC-6 and PRO-C6) were not statistically different from controls, however few patients presented with high biomarker levels (e.g. colon cancer for IC-6 and ovarian cancer for PRO-C6). In detail, C6Ma1 was significantly elevated in patients with cancer of the breast, colon, ovary, pancreas and lung (SCLC and NSCLC) compared to controls. No significant difference was seen for patients with gastric cancer, malignant melanoma and prostate cancer, albeit the median levels were higher in both melanoma and prostate cancer patients. Similar to C6Ma1, C6Ma3 was significantly elevated in patients with cancer of the breast, colon, pancreas and lung (SCLC and NSCLC) compared to controls. No significant difference was seen for patients with gastric cancer, ovarian cancer, malignant melanoma and prostate cancer, albeit median levels were higher in both melanoma, ovarian and prostate cancer patients. For both C6Ma1 and C6Ma3 the patient-to-patient variation is relatively high and in absolute numbers (ng/ml) C6Ma1 was more abundant in serum than C6Ma3, both in healthy controls and in cancer patients. IC-6 and PRO-C6 showed similar absolute abundancy.Figure 2Serum levels (ng/ml) of the four different type VI collagen (COL6) fragments (see [Table 1](#t0005){ref-type="table"} for details) in healthy controls and in patients with various solid tumor types. Biomarker levels from controls were compared to individual patient groups by a Kruskal-Wallis test adjusted for multiple comparisons with Dunn\'s test. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, \*\*\*\**P* \< .0001. SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer.Figure 2

Next, the levels of the four COL6 fragments were compared according to disease stage (TNM stage), by dividing the cancer patients into early stage (1 + 2) or late stage (3 + 4) cancer at time of diagnosis. No significant difference was detected between early and late stage for any of the markers ([Figure 3](#f0015){ref-type="fig"}). Still, there was a trend towards elevated levels in late stage for PRO-C6 (*P* = .072) and IC-6 (*P* = .177), whereas C6Ma1 (*P* = .45) and C6Ma3 (*P* = .79).Figure 3Serum levels (ng/ml) of four different type VI collagen (COL6) fragments measured in patients with various solid tumor types according to early (1 + 2) vs late (3 + 4) stage of disease as well as three patients with unknown stage. Each tumor indication has been given its own symbol. Biomarker levels were compared by the Mann--Whitney test. No significant differences could be detected. SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer.Figure 3

MMP-Generated COL-6 Fragments (C6Ma1, C6Ma3) Correlate when Measured in Serum {#s0040}
-----------------------------------------------------------------------------

All four COL6 fragments were compared pairwise and evaluated by Spearman correlation coefficient, r. The analyses included both the healthy control and the cancer patients. Only the two MMP-generated fragments C6Ma1 and C6Ma3 were highly correlated (r: 0.739, *P* \< .0001) when compared pairwise ([Table 3](#t0015){ref-type="table"}). A trend was also seen towards a weak correlation between biomarkers of the same alpha-chain (C6Ma3 vs PRO-C6, r: 0.216, *P* = .058 and C6Ma1 vs IC-6, r: 0.207, *P* = .058).Table 3Correlations between the four COL6 serum biomarkers.Table 3BiomarkersSpearman, *rP*C6Ma1 vs C6Ma30.739\<.0001C6Ma3 vs PRO-C60.216.058C6Ma1 vs IC-60.207.088C6Ma3 vs IC-60.163.179IC-6 vs PRO-C60.123.313C6Ma1 vs PRO-C60.042.715

MMP-Generated COL-6 Fragments can Discriminate Between Cancer Patients and Healthy Controls (Diagnostic Power) {#s0045}
--------------------------------------------------------------------------------------------------------------

To evaluate the diagnostic power of the COL6 fragments the AUROC was calculated. As shown in [Figure 4](#f0020){ref-type="fig"}, the diagnostic power of C6Ma1 and C6Ma3 was highly significant with an AUROC of 0.90 (*P* \< .0001) and of 0.87 (*P* \< .0001), respectively when comparing healthy control to patients with cancer. In contrast, neither IC-6 nor PRO-C6 had any diagnostic power with an AUROC of 0.59 (*P* = .311) and 0.53 (*P* = .747), respectively. As the biomarkers did correlate with r: 0.739, *P* \< .0001 to the best ([Table 3](#t0015){ref-type="table"}), the additive effect on the diagnostic power was investigated by combining all four markers. When combining all biomarkers, a diagnostic power of 0.95 (*P* \< .0001) was achieved ([Figure 5](#f0025){ref-type="fig"}), indicating that the combination of all biomarkers leads to almost complete discrimination between healthy controls and cancer patients.Figure 4Diagnostic power evaluated by receiver operating characteristics (ROC) curve analysis for the ability of the four serum COL-6 fragments to separate healthy controls from patients with cancer. AUROC, area under the ROC curve.Figure 4Figure 5Diagnostic power evaluated by receiver operating characteristics (ROC) curve analysis for the ability of the four serum COL-6 fragments combined to separate healthy controls from patients with cancer. AUROC, area under the ROC curve.Figure 5

Discussion {#s0050}
==========

While the importance of COL6 in cancer is well established, much less is known regarding the biomarker potential. In the present study four specific COL6 fragments were measured in serum as potential biomarkers for cancer. Interestingly, MMP-generated COL6 fragments (C6Ma1, C6Ma3) were the best biomarkers of the four COL-6 fragments evaluated. Both C6Ma1 and C6Ma3 were significantly elevated across several different cancer indications when compared to controls, had a relatively large patient-to-patient variation within each patient-group and showed promising diagnostic accuracy. Altogether, this supports that quantifying MMP-generated COL6 remodeling/degradation have biomarker potential in cancer. Furthermore, the significant correlation between C6Ma1 and C6Ma3 indicates that both the COL6a1 and COL6a3 chains are degraded in the same patients as part of tumorigenesis. As both markers were elevated in all cancer stages, they may potentially be applied in patients with early, as well as late stage of cancer. The fact the MMP-generated collagen fragments have biomarker potential in cancer is no surprise. It has previously been established from the same cohort, and other cohorts of cancer patients, that fragments of MMP-degraded type I collagen, MMP-degraded type III collagen and MMP-degraded type IV collagen all are elevated in cancer compared to healthy controls [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160], [@bb0165], [@bb0170].

To our knowledge, only few other studies have evaluated the clinical significance of measuring COL6 in serum from cancer patients. COL6a3 fragments have been found upregulated in the circulation of patients with colorectal cancer compared to healthy controls [@bb0175]. Likewise, one study focused on quantifying COL6a3 in serum from patients with pancreatic ductal adenocarcinomas and found higher levels in cases compared to controls [@bb0180]. Another study evaluated levels of COL6a1/a2 chains in serum from patients with malignant melanoma and reached similar conclusions [@bb0185]. This is however the first study to show cancer serum biomarker potential of (MMP-degraded) COL6 in serum across several cancer indications.

While this is the first study to show a link between MMP-degraded COL6 and different cancer types, several other non-oncology studies have evaluated the biomarker potential of MMP-degraded COL6. MMP-degraded COL6 has been found to be increased in liver fibrosis [@bb0190], to correlate with muscle mass and anabolic response during training in young men [@bb0195] and to associate with exacerbations [@bb0200], predict lung function changes [@bb0205] and predict mortality [@bb0210] in chronic obstructive pulmonary disease (COPD). C6Ma1 has also been found relevant for idiopathic pulmonary fibrosis (IPF), with longitudinal changes being significantly higher in patients with progressive disease [@bb0215].

Taken together, these findings support that MMP-mediated COL6 remodeling is an important component of tumorigenesis, but also that it may reflect a more common fibrosis-related pathological event. For instance, it has been reported that C6Ma1 is also been found in patients with IPF and COPD, which clearly limits the relevance of this marker for lung cancer diagnosis [@bb0200], [@bb0205], [@bb0210], [@bb0215]. Still, MMP\'s are well characterized and important players in both fibrosis and cancer. Interestingly, more attention is drawn towards tumor fibrosis (desmoplasia) due to the association with a poor prognosis and lack of response to treatment in cancer patients with a severe desmoplastic reaction [@bb0220], [@bb0225]. Clearly, novel tools are needed to quantify the desmoplastic reaction in oncology, and future studies should evaluate C6Ma1 and C6Ma3 in this context. As the present study only evaluated the turnover of COL6a1 and COL6a3, future studies should evaluate the turnover of COL6a2 which has also been linked to MMP activity and hence tumorigenesis [@bb0230].

The COL6 fragments IC-6 and PRO-C6 have also been evaluated in other diseases. IC-6 has been shown to correlate with muscle mass in young subjects [@bb0195]. PRO-C6 has been more extensively studied. From a biomarker perspective serum PRO-C6 has been found associated with chronic and diabetic kidney disease [@bb0235], [@bb0240]. Likewise, in type 2 diabetic patients PRO-C6 was found to predict response to a PPAR agonist treatment [@bb0245]. PRO-C6 has also shown prognostic value in COPD [@bb0210]. Interestingly, a preliminary study has shown that high pre-treatment levels of PRO-C6 predicts outcome in patients with metastatic colorectal cancer when treated with chemotherapy [@bb0250]. These findings indicate that PRO-C6 could be prognostic in cancer, which is also supported by the borderline significant association between cancer stage and PRO-C6 levels (*P* = .072, when comparing early vs late stage patients). As mentioned, PRO-C6 targets the signaling molecule endothrophin. The protease(s) responsible for generating endothrophin is currently unknown, although in one study incorrectly folded type VI collagen was found in MMP-11 deficient mice [@bb0255]. Thus, studies are warranted to evaluate PRO-C6/endothrophin in the oncology setting.

While the present study is limited by a relatively small size, the quantification of COL6 remodeling seems promising. As biomarker levels are different in the analyzed tumor types, it is conceivable that the diagnostic power of C6Ma1 and C6Ma3 is driven by specific tumor types showing the highest biomarker levels (e.g. pancreatic tumors, NSCLC) and further investigations are required to elucidate how specific tumor types are more associated with COL-6 remodeling. To fully analyze the diagnostic/prognostic applicability of the COL-6 fragments used here, more patients, other types of cancer and diseases with a similar pathology (e.g. fibrosis) should be evaluated as well. The cross-sectional nature of the study is also a limiting factor in the present study, and a larger longitudinal study is therefore needed to understand the full potential of these biomarkers.

In conclusion, MMP-generated COL6 fragments (C6Ma1, C6Ma3) were elevated in serum from cancer patients compared to controls and had promising diagnostic accuracy. This supports that MMP-mediated COL6 remodeling is an important component of tumorigenesis and future studies are needed to determine biological and clinical applicability of quantifying various COL6 fragments in serum in relation to cancer.
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[^1]: Significantly different (*P* \< .05) from healthy controls (Kruskal-Wallis test adjusted with Dunn\'s test for comparing each cancer group to the healthy controls). NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer.
